Page last updated: 2024-08-24

lamivudine and Dyslipidemia

lamivudine has been researched along with Dyslipidemia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Cao, TZ; He, Y; Liu, JY; Liu, XN; Rao, M; Song, Y; Sun, LQ; Tian, YM; Wang, H; Xu, LM; Zhang, LK; Zhao, F; Zhou, Y	1
Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D	1
Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF	1
Crane, HM; Feldman, BJ; Grunfeld, C; Kitahata, MM; Lederman, MM; Moore, R; Mugavero, MJ; Rodriguez, B; Saag, MS; Van Rompaey, S; Willig, JH	1

Trials

1 trial(s) available for lamivudine and Dyslipidemia

Article	Year
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Antiviral therapy, 2010, Volume: 15, Issue:8 Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir	2010

Article

Year

Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.

Antiviral therapy, 2010, Volume: 15, Issue:8

Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir

2010

Other Studies

3 other study(ies) available for lamivudine and Dyslipidemia

Article	Year
Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen. Chinese medical journal, 2020, Dec-05, Volume: 133, Issue:23 Topics: Aged; Anti-HIV Agents; China; Dyslipidemias; HIV; HIV Infections; Humans; Lamivudine; Lipids; Risk Factors	2020
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients. European journal of internal medicine, 2013, Volume: 24, Issue:6 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine	2013
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS (London, England), 2011, Jan-14, Volume: 25, Issue:2 Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Didanosine; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Stavudine	2011